Literature DB >> 19109227

Hidden abnormalities and novel classification of t(15;17) acute promyelocytic leukemia (APL) based on genomic alterations.

Tadayuki Akagi1, Lee-Yung Shih, Motohiro Kato, Norihiko Kawamata, Go Yamamoto, Masashi Sanada, Ryoko Okamoto, Carl W Miller, Der-Cherng Liang, Seishi Ogawa, H Phillip Koeffler.   

Abstract

Acute promyelocytic leukemia (APL) is a hematopoietic malignant disease characterized by the chromosomal translocation t(15;17), resulting in the formation of the PML-RARA gene. Here, 47 t(15;17) APL samples were analyzed with high-density single-nucleotide polymorphism microarray (50-K and 250-K SNP-chips) using the new algorithm AsCNAR (allele-specific copy-number analysis using anonymous references). Copy-number-neutral loss of heterozygosity (CNN-LOH) was identified at chromosomes 10q (3 cases), 11p (3 cases), and 19q (1 case). Twenty-eight samples (60%) did not have an obvious alteration (normal-copy-number [NC] group). Nineteen samples (40%) showed either one or more genomic abnormalities: 8 samples (17%) had trisomy 8 either with or without an additional duplication, deletion, or CNN-LOH (+8 group); and 11 samples (23%) had genomic abnormalities without trisomy 8 (other abnormalities group). These chromosomal abnormalities were acquired somatic mutations. Interestingly, FLT3-ITD mutations (11/47 cases) occurred only in the group with no genomic alteration (NC group). Taken together, these results suggest that the pathway of development of APL differs in each group: FLT3-ITD, trisomy 8, and other genomic changes. Here, we showed for the first time hidden abnormalities and novel disease-related genomic changes in t(15;17) APL.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19109227      PMCID: PMC2647673          DOI: 10.1182/blood-2007-12-130260

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  41 in total

1.  FLT3 internal tandem duplication mutations associated with human acute myeloid leukemias induce myeloproliferative disease in a murine bone marrow transplant model.

Authors:  Louise M Kelly; Qing Liu; Jeffrey L Kutok; Ifor R Williams; Christina L Boulton; D Gary Gilliland
Journal:  Blood       Date:  2002-01-01       Impact factor: 22.113

2.  Two cases of myeloid disorders and a t(8;12) (q12;p13).

Authors:  J M Hernández; M B González; J L García; M T Ferro; N C Gutiérrez; P Marynen; J F San Miguel
Journal:  Haematologica       Date:  2000-01       Impact factor: 9.941

3.  The t(15;17) translocation of acute promyelocytic leukaemia fuses the retinoic acid receptor alpha gene to a novel transcribed locus.

Authors:  H de Thé; C Chomienne; M Lanotte; L Degos; A Dejean
Journal:  Nature       Date:  1990-10-11       Impact factor: 49.962

4.  Internal tandem duplication and Asp835 mutations of the FMS-like tyrosine kinase 3 (FLT3) gene in acute promyelocytic leukemia.

Authors:  Lee-Yung Shih; Ming-Chung Kuo; Der-Cherng Liang; Chein-Fuang Huang; Tung-Liang Lin; Jin-Hou Wu; Po-Nan Wang; Po Dunn; Chang-Liang Lai
Journal:  Cancer       Date:  2003-09-15       Impact factor: 6.860

5.  Frequent genomic abnormalities in acute myeloid leukemia/myelodysplastic syndrome with normal karyotype.

Authors:  Tadayuki Akagi; Seishi Ogawa; Martin Dugas; Norihiko Kawamata; Go Yamamoto; Yasuhito Nannya; Masashi Sanada; Carl W Miller; Amanda Yung; Susanne Schnittger; Torsten Haferlach; Claudia Haferlach; H Phillip Koeffler
Journal:  Haematologica       Date:  2009-01-14       Impact factor: 9.941

6.  The PML-RAR alpha fusion mRNA generated by the t(15;17) translocation in acute promyelocytic leukemia encodes a functionally altered RAR.

Authors:  H de Thé; C Lavau; A Marchio; C Chomienne; L Degos; A Dejean
Journal:  Cell       Date:  1991-08-23       Impact factor: 41.582

7.  Establishment of a new peroxidase-positive human myeloid cell line, PL-21.

Authors:  I Kubonishi; K Machida; K Niiya; H Sonobe; Y Ohtsuki; K Iwata; I Miyoshi
Journal:  Blood       Date:  1984-02       Impact factor: 22.113

8.  A model of APL with FLT3 mutation is responsive to retinoic acid and a receptor tyrosine kinase inhibitor, SU11657.

Authors:  Jastinder Sohal; Vernon T Phan; Philip V Chan; Elizabeth M Davis; Bhumi Patel; Louise M Kelly; Tinya J Abrams; Anne Marie O'Farrell; D Gary Gilliland; Michelle M Le Beau; Scott C Kogan
Journal:  Blood       Date:  2002-12-19       Impact factor: 22.113

9.  PML/RARalpha and FLT3-ITD induce an APL-like disease in a mouse model.

Authors:  Louise M Kelly; Jeffrey L Kutok; Ifor R Williams; Christina L Boulton; Sonia M Amaral; David P Curley; Timothy J Ley; D Gary Gilliland
Journal:  Proc Natl Acad Sci U S A       Date:  2002-06-11       Impact factor: 11.205

10.  NB4, a maturation inducible cell line with t(15;17) marker isolated from a human acute promyelocytic leukemia (M3).

Authors:  M Lanotte; V Martin-Thouvenin; S Najman; P Balerini; F Valensi; R Berger
Journal:  Blood       Date:  1991-03-01       Impact factor: 22.113

View more
  26 in total

1.  Treatment-influenced associations of PML-RARα mutations, FLT3 mutations, and additional chromosome abnormalities in relapsed acute promyelocytic leukemia.

Authors:  Robert E Gallagher; Barry K Moser; Janis Racevskis; Xavier Poiré; Clara D Bloomfield; Andrew J Carroll; Rhett P Ketterling; Diane Roulston; Esther Schachter-Tokarz; Da-Cheng Zhou; I-Ming L Chen; Richard Harvey; Greg Koval; Dorie A Sher; James H Feusner; Martin S Tallman; Richard A Larson; Bayard L Powell; Frederick R Appelbaum; Elisabeth Paietta; Cheryl L Willman; Wendy Stock
Journal:  Blood       Date:  2012-06-25       Impact factor: 22.113

2.  Activation of a promyelocytic leukemia-tumor protein 53 axis underlies acute promyelocytic leukemia cure.

Authors:  Julien Ablain; Kim Rice; Hassane Soilihi; Aurélien de Reynies; Saverio Minucci; Hugues de Thé
Journal:  Nat Med       Date:  2014-01-12       Impact factor: 53.440

3.  Single nucleotide polymorphism genomic arrays analysis of t(8;21) acute myeloid leukemia cells.

Authors:  Tadayuki Akagi; Lee-Yung Shih; Seishi Ogawa; Joachim Gerss; Stephen R Moore; Rhona Schreck; Norihiko Kawamata; Der-Cherng Liang; Masashi Sanada; Yasuhito Nannya; Stefan Deneberg; Vasilios Zachariadis; Ann Nordgren; Jee Hoon Song; Martin Dugas; Sören Lehmann; H Phillip Koeffler
Journal:  Haematologica       Date:  2009-09       Impact factor: 9.941

Review 4.  Acute promyelocytic leukaemia: novel insights into the mechanisms of cure.

Authors:  Hugues de Thé; Zhu Chen
Journal:  Nat Rev Cancer       Date:  2010-10-22       Impact factor: 60.716

Review 5.  How animal models of leukaemias have already benefited patients.

Authors:  Julien Ablain; Rihab Nasr; Jun Zhu; Ali Bazarbachi; Valérie Lallemand-Breittenbach; Hugues de Thé
Journal:  Mol Oncol       Date:  2013-02-11       Impact factor: 6.603

6.  Additional chromosome abnormalities in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and chemotherapy.

Authors:  José Cervera; Pau Montesinos; Jesús M Hernández-Rivas; María J Calasanz; Anna Aventín; María T Ferro; Elisa Luño; Javier Sánchez; Edo Vellenga; Chelo Rayón; Gustavo Milone; Javier de la Serna; Concha Rivas; José D González; Mar Tormo; Elena Amutio; Marcos González; Salut Brunet; Bob Lowenberg; Miguel A Sanz
Journal:  Haematologica       Date:  2009-11-10       Impact factor: 9.941

7.  Gain of MYC underlies recurrent trisomy of the MYC chromosome in acute promyelocytic leukemia.

Authors:  Letetia Jones; Guangwei Wei; Sabina Sevcikova; Vernon Phan; Sachi Jain; Angell Shieh; Jasmine C Y Wong; Min Li; Joshua Dubansky; Mei Lin Maunakea; Rachel Ochoa; George Zhu; Thelma R Tennant; Kevin M Shannon; Scott W Lowe; Michelle M Le Beau; Scott C Kogan
Journal:  J Exp Med       Date:  2010-11-08       Impact factor: 14.307

8.  Acquired copy number alterations in adult acute myeloid leukemia genomes.

Authors:  Matthew J Walter; Jacqueline E Payton; Rhonda E Ries; William D Shannon; Hrishikesh Deshmukh; Yu Zhao; Jack Baty; Sharon Heath; Peter Westervelt; Mark A Watson; Michael H Tomasson; Rakesh Nagarajan; Brian P O'Gara; Clara D Bloomfield; Krzysztof Mrózek; Rebecca R Selzer; Todd A Richmond; Jacob Kitzman; Joel Geoghegan; Peggy S Eis; Rachel Maupin; Robert S Fulton; Michael McLellan; Richard K Wilson; Elaine R Mardis; Daniel C Link; Timothy A Graubert; John F DiPersio; Timothy J Ley
Journal:  Proc Natl Acad Sci U S A       Date:  2009-07-27       Impact factor: 11.205

Review 9.  p53 as an Effector or Inhibitor of Therapy Response.

Authors:  Julien Ablain; Brigitte Poirot; Cécile Esnault; Jacqueline Lehmann-Che; Hugues de Thé
Journal:  Cold Spring Harb Perspect Med       Date:  2015-12-04       Impact factor: 6.915

Review 10.  Genomic analysis of acute myeloid leukemia: potential for new prognostic indicators.

Authors:  Elizabeth A Eklund
Journal:  Curr Opin Hematol       Date:  2010-03       Impact factor: 3.284

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.